AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18835696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary valve replacement (PVR)
Number of subjects: 58
Study 16487205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 102
Study 16487205 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 102
Study 14515286 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (thoracic epidural anaesthesia‐analgesia) with bupivacaine and fentanyl
Number of subjects: 38
Study 14515286 — intervention group
Group type: COMPARATOR
Intervention: PCA (patient-controlled analgesia) with morphine
Number of subjects: 38
Study 12669749 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient distractor presented within 600 ms before the target
Number of subjects: 7
Study 12669749 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractors presented at fixation
Number of subjects: 7
Study 12669749 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial shifts in attentional focus ruled out
Number of subjects: 7
Study 10534571 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients in target detection task
Number of subjects: 0
Study 10534571 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients in short-term memory task
Number of subjects: 0
Study 10534571 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients in memory task
Number of subjects: 0
Study 10534571 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients in self-paced movements and expectancy and reaction time (CNV) tasks
Number of subjects: 0
Study 10534571 — intervention group
Group type: COMPARATOR
Intervention: Healthy normals
Number of subjects: 0
Study 7705704 — intervention group
Group type: EXPERIMENTAL
Intervention: FUDR (22.5 mg/m2) and cisplatin (6.75 mg/m2) administered with concurrent whole pelvis radiation (40-50 Gy)
Number of subjects: 16
Study 7705704 — intervention group
Group type: EXPERIMENTAL
Intervention: FUDR and cisplatin regimen
Number of subjects: 16
Study 7705704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level 4 (22.5 mg/m2 FUDR and 6.75 mg/m2 cisplatin)
Number of subjects: 16
Study 7705704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level 5 (27 mg/m2 FUDR and 8 mg/m2 cisplatin)
Number of subjects: 16
Study 2649463 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 12 g/m2 applied within 6 weeks
Number of subjects: 331
Study 2649463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 73856 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiometrics automatic blood-pressure recorder
Number of subjects: 0
Study 73856 — intervention group
Group type: COMPARATOR
Intervention: Direct recordings
Number of subjects: 0
Study 29621894 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic delivery of the Lidcombe Program
Number of subjects: 49
Study 29621894 — intervention group
Group type: COMPARATOR
Intervention: Telehealth delivery of the Lidcombe Program
Number of subjects: 49
Study 29621894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Clinic and Telehealth)
Number of subjects: 49
Study 27882399 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography night
Number of subjects: 97
Study 27882399 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP titration night
Number of subjects: 97
Study 27882399 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS
Number of subjects: 97
Study 26010727 — intervention group
Group type: EXPERIMENTAL
Intervention: Esperanza y Vida program delivered by lay health advisor cancer survivors
Number of subjects: 908
Study 23473794 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phospholipid 16:0
Number of subjects: 1576
Study 21277706 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco smoking
Number of subjects: 37
Study 21277706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavor-matched, tobacco-free preparation)
Number of subjects: 37
Study 21277706 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco smoking and Placebo
Number of subjects: 37
Study 19591885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gruel made from instant infant flour
Number of subjects: 144
Study 19591885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gruel made from food supplement containing amylases
Number of subjects: 144
Study 19591885 — intervention group
Group type: COMPARATOR
Intervention: Home-made complementary foods
Number of subjects: 144
Study 17728549 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0
Study 17728549 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment approaches (laser photocoagulation, PDT, subretinal surgery, novel anti-angiogenic drugs)
Number of subjects: 0
Study 17728549 — intervention group
Group type: EXPERIMENTAL
Intervention: Case series and individual case control studies
Number of subjects: 0
Study 15139406 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4914
Study 15139406 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 4914
Study 11230490 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocet (liposome-encapsulated doxorubicin) + cyclophosphamide
Number of subjects: 297
Study 11230490 — intervention group
Group type: COMPARATOR
Intervention: Conventional doxorubicin + cyclophosphamide
Number of subjects: 297
Study 11230490 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocet + cyclophosphamide
Number of subjects: 297
Study 9988986 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectic patients
Number of subjects: 114
Study 9988986 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovering anorectics
Number of subjects: 114
Study 9988986 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 114
Study 7995624 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (to raise plasma insulin 100 microU/mL)
Number of subjects: 9
Study 7995624 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 9
Study 7995624 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 3294036 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release terbutaline (b.i.d. 0.25 mg/kg per day)
Number of subjects: 11
Study 3294036 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline (5.31 mg/kg morning and 10.62 mg/kg evening)
Number of subjects: 11
Study 3294036 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline
Number of subjects: 11
Study 3294036 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release terbutaline
Number of subjects: 11
Study 30799231 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA
Number of subjects: 56
Study 30799231 — intervention group
Group type: COMPARATOR
Intervention: OM3-EE
Number of subjects: 56
Study 27918705 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 27
Study 27918705 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 27
Study 25846661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 106
Study 25846661 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 106
Study 23656810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) + drug group
Number of subjects: 133
Study 23656810 — intervention group
Group type: COMPARATOR
Intervention: Drug group (mometasone furoate nasal spray and desloratadine tablets)
Number of subjects: 133
Study 23656810 — intervention group
Group type: COMPARATOR
Intervention: Drug group
Number of subjects: 133
Study 22188590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg once daily (OD)
Number of subjects: 190
Study 22188590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg twice daily (BD)
Number of subjects: 190
Study 22188590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 μg OD
Number of subjects: 190
Study 22188590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 μg BD
Number of subjects: 190
Study 22188590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 19414836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-duration, ultrasonography-guided anticoagulation
Number of subjects: 538
Study 19414836 — intervention group
Group type: COMPARATOR
Intervention: Fixed-duration anticoagulation
Number of subjects: 538
Study 19414836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-duration, ultrasonography-guided anticoagulation (for unprovoked DVT)
Number of subjects: 538
Study 19414836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-duration, ultrasonography-guided anticoagulation (for secondary DVT)
Number of subjects: 538
Study 17061440 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (nutritional doses)
Number of subjects: 5086
Study 17061440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5086
Study 14690730 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCAB surgery
Number of subjects: 0
Study 14690730 — intervention group
Group type: COMPARATOR
Intervention: OFFCAB surgery
Number of subjects: 0
Study 14690730 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (both ONCAB and OFFCAB)
Number of subjects: 0
Study 11712619 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg o.d.)
Number of subjects: 313
Study 11712619 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50‐100 mg o.d.)
Number of subjects: 313
Study 9446006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (I, n = 17)
Number of subjects: 51
Study 9446006 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (II, n = 17)
Number of subjects: 51
Study 9446006 — intervention group
Group type: COMPARATOR
Intervention: No calcium channel blockers (III, n = 17)
Number of subjects: 51
Study 11548224 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate 500 mg t.i.d. for 4 weeks
Number of subjects: 252
Study 11548224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 3074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide at 600 micrograms (6 subjects)
Number of subjects: 23
Study 3074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide at 400 micrograms t.i.d. (6 subjects)
Number of subjects: 23
Study 3074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline at 300 mg b.i.d. (11 subjects)
Number of subjects: 23
Study 3074291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 23
Study 3074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (both dosages)
Number of subjects: 23
Study 3074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 23
Study 3074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 23
Study 31132111 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX + 2 g oral curcumin/d (CUFOX)
Number of subjects: 28
Study 31132111 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 28
Study 26818096 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg mirtazapine (n = 8)
Number of subjects: 24
Study 26818096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 24
Study 25682769 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma release assay (IGRA)
Number of subjects: 807
Study 25682769 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 807
Study 25682769 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon TB Gold (QFT-G)
Number of subjects: 807
Study 23829057 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral ivermectin 200 microg/kg body weight
Number of subjects: 440
Study 23829057 — intervention group
Group type: COMPARATOR
Intervention: Two applications of topical lindane lotion 1% with a 1-week interval
Number of subjects: 440
Study 21917377 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial training sessions
Number of subjects: 0
Study 21917377 — intervention group
Group type: COMPARATOR
Intervention: Biomechanics training sessions
Number of subjects: 0
Study 18265647 — intervention group
Group type: EXPERIMENTAL
Intervention: OS‐1 (oral rehydration solution)
Number of subjects: 44
Study 18265647 — intervention group
Group type: COMPARATOR
Intervention: KN3B (intravenous maintenance solution)
Number of subjects: 44
Study 15119979 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 2442
Study 12960999 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (200 mg/kg infused intravenously over 4 hours, 12 and 3 hours before PCI, and 500 mg over 10 minutes prior to stent implantation, followed by oral supplementation of 6 g/day for 14 days after PCI)
Number of subjects: 60
Study 12960999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9689421 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN) 60 mg/d
Number of subjects: 24
Study 9689421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerithritol tetranitrate (PETN) 240 mg/d
Number of subjects: 24
Study 9689421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerithritol tetranitrate (PETN) 150 mg/d
Number of subjects: 24
Study 9689421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7532087 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (6 million kallikrein inactivator units)
Number of subjects: 120
Study 7532087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (3 million kallikrein inactivator units)
Number of subjects: 120
Study 7532087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (3 million kallikrein inactivator units) with autologous blood transfusions
Number of subjects: 120
Study 2673045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate-5-fluorouracil (MF)
Number of subjects: 133
Study 2673045 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil alone (F)
Number of subjects: 133
Study 28497259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproic acid (15 to 150 mg/kg)
Number of subjects: 59
Study 28497259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 27598804 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD) combined with high-dose radiation therapy (HDRT)
Number of subjects: 355
Study 27598804 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen deprivation (STAD) combined with high-dose radiation therapy (HDRT)
Number of subjects: 355
Study 25457733 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered intervention (Young Adults Eating and Active for Health)
Number of subjects: 1639
Study 25457733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1639
Study 22248761 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with bupivacaine and epidural morphine
Number of subjects: 80
Study 22248761 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs and intravenous morphine
Number of subjects: 80
Study 20658749 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy interruption
Number of subjects: 332
Study 20658749 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy continuation
Number of subjects: 332
Study 18845605 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants
Number of subjects: 682
Study 18845605 — intervention group
Group type: COMPARATOR
Intervention: Social visits
Number of subjects: 682
Study 16117862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of bone‐marrow cells (BMCs)
Number of subjects: 20
Study 16117862 — intervention group
Group type: COMPARATOR
Intervention: Diluted serum (control)
Number of subjects: 20
Study 12842060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured group
Number of subjects: 74
Study 12842060 — intervention group
Group type: COMPARATOR
Intervention: Not sutured group
Number of subjects: 74
Study 11057001 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic cues
Number of subjects: 0
Study 11057001 — intervention group
Group type: COMPARATOR
Intervention: Combination of orthographic and phonological cues
Number of subjects: 0
Study 8853729 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg beta-carotene orally three times daily and multivitamins
Number of subjects: 72
Study 8853729 — intervention group
Group type: COMPARATOR
Intervention: Placebo and multivitamins
Number of subjects: 72
Study 1353367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 0
Study 1353367 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 0
Study 6391665 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuart Prenatal tablets
Number of subjects: 40
Study 6391665 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuart-natal 1 + 1
Number of subjects: 40
Study 6391665 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 40
Study 6391665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31487577 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for cannabis use disorder (CUD) over 9 sessions
Number of subjects: 198
Study 31487577 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for cannabis use disorder (CUD)
Number of subjects: 198
Study 29270622 — intervention group
Group type: EXPERIMENTAL
Intervention: External Vibration Therapy (EVT)
Number of subjects: 27
Study 29270622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 26762883 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise care
Number of subjects: 182
Study 26762883 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 182
Study 24842917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 19
Study 24842917 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 19
Study 21976631 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT)
Number of subjects: 1406
Study 21976631 — intervention group
Group type: EXPERIMENTAL
Intervention: Further investigations (FDG-PET or CT-guided FNAB)
Number of subjects: 1406
Study 21976631 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment based on radiation exposure
Number of subjects: 1406
Study 20852060 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) 3 days per week for 16 weeks
Number of subjects: 53
Study 20852060 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 53
Study 20852060 — intervention group
Group type: COMPARATOR
Intervention: Attention control (biweekly follow‐up telephone calls)
Number of subjects: 53
Study 17664342 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 60
Study 17664342 — intervention group
Group type: COMPARATOR
Intervention: Open Bankart repair
Number of subjects: 60
Study 17664342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16338450 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study 12222942 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited approach
Number of subjects: 65
Study 12222942 — intervention group
Group type: COMPARATOR
Intervention: Extended approach
Number of subjects: 65
Study 10812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (100,000 KIU) applied locally to the wound surface after IMA harvesting in group C1
Number of subjects: 275
Study 10812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU) applied locally to the wound surface and into the pericardial cavity in group D1
Number of subjects: 275
Study 10812681 — intervention group
Group type: COMPARATOR
Intervention: Venous grafts in group A2
Number of subjects: 275
Study 10812681 — intervention group
Group type: COMPARATOR
Intervention: IMA used in group B2
Number of subjects: 275
Study 10812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU) in group D2
Number of subjects: 275
Study 7726440 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (2.4 +/- 0.7 mg.kg‐1.h‐1)
Number of subjects: 10
Study 7726440 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam infusion (0.13 +/- 0.04 mg.kg‐1.h‐1)
Number of subjects: 10
Study 7726440 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nonsedating bolus dose propofol (0.4 mg/kg)
Number of subjects: 10
Study 7726440 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 10
Study 1768821 — intervention group
Group type: EXPERIMENTAL
Intervention: Various strategies to manage cardiopulmonary bypass (hypothermia vs normothermia, presence vs absence of arterial microfilters, presence vs absence of glucose-containing solution in pump prime)
Number of subjects: 0
Study 1768821 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study 1768821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedure and management of cardiopulmonary bypass
Number of subjects: 0
Study 6120738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 42
Study 6120738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6120738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (open assessment)
Number of subjects: 42
Study 31774340 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions across trials
Number of subjects: 18
Study 31774340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30336812 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 2037
Study 30336812 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 2037